NCT00049673 2023-09-13
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
Clinical Trials
12 trialsNCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
NCT00075829 2021-11-01
BMT CTN 0102
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00792142 2021-08-19
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT00538733 2021-05-24
T-BiRD
Weill Medical College of Cornell University
Phase 2 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT01927718 2019-04-29
Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
M.D. Anderson Cancer Center
Phase NA Terminated
NCT00538824 2018-06-06
DexTR
Weill Medical College of Cornell University
Phase 2 Terminated
NCT00523848 2017-02-23
Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
Roswell Park Cancer Institute
Phase 2 Completed
NCT00458705 2016-01-22
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00083382 2015-06-24
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
University of Arkansas
Phase 2 Completed
NCT00432458 2012-07-04
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
Phase 3 Completed